MOR106 is the first publicly disclosed human monoclonal antibody directed against IL-17C in clinical development worldwide. MOR106 is also the first antibody from MorphoSys’s Ylanthia platform to enter clinical development. In preclinical models, IL-17C has been shown to play an important role in inflammatory skin disorders. MOR106 is currently in clinical development for the treatment of atopic dermatitis, a debilitating chronic inflammatory skin disease. A randomized placebo-controlled phase 1 study, testing MOR106 in healthy volunteers and in patients suffering from atopic dermatitis, was successfully completed. A subsequent phase 2 study started in the quater of 2018.